Cargando…
Modified solid in oil nanodispersion containing vemurafenib-lipid complex- in vitro/ in vivo study
Background: Vemurafenib (VEM) was a licensed drug for the treatment of skin melanoma and is available only in the market as oral tablets prescribed in huge doses (1920 mg/day). One reason for the high dose is vemurafenib's low oral bioavailability. Methods: VEM-lipid complex (DLC) was predicted...
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
F1000 Research Limited
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9627402/ https://www.ncbi.nlm.nih.gov/pubmed/36339973 http://dx.doi.org/10.12688/f1000research.123041.2 |